Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott Gets Lift From Virus Tests -- WSJ

share with twitter share with LinkedIn share with facebook
07/17/2020 | 02:48am EDT

By Matt Grossman

Abbott Laboratories recorded a surge in revenue in its U.S. diagnostics business during the second quarter, fueled by strong demand for the company's Covid-19 testing.

Revenue for the Abbott Park, Ill.-based medical company's U.S. diagnostics segment climbed 23% to $857 million in the period. World-wide, Abbott's diagnostics business grew 4.7% to $1.99 billion.

Abbott provides testing related to Covid-19 on three different platforms. It offers both lab-based and on-site tests for current infections, and provides a lab-based antibody test to check if a person was previously infected with the virus. A decline in testing services for other conditions tempered the segment's results, however.

Abbott Chief Executive Robert Ford told analysts on a conference call Thursday that he expected demand for the company's Covid-19 testing to endure beyond the end of the year.

"Even when you have a vaccine, I think that I can see patients going to a physician's office with a fever, and they want to know: ... Is it the flu? Is it Covid?" Mr. Ford said. "We think that the capacity that we're building is not only for a high demand during the next 12, 18 or 24 months, but a steady state."

Overall, Abbott's sales decreased as the pandemic disrupted demand for its medical devices used in procedures unrelated to the new coronavirus. Sales of medical devices fell 21.2% to $2.42 billion.

The company's revenue overall declined to $7.33 billion from the $7.98 billion recorded in last year's second quarter -- a drop of 8.2%, or 5.4% on an organic basis, which excluded the impact of foreign exchange. Analysts polled by FactSet had estimated quarterly revenue of $6.81 billion.

Sales for Abbott's pharmaceuticals business -- which serves international markets -- declined 8.6% in the quarter to $1.01 billion. Strong growth for the segment in China was offset in countries experiencing continued Covid-19 outbreaks such as Russia, Brazil and Colombia.

The company's overall profit declined to $537 million, or 30 cents a share, from $1.01 billion, or 56 cents a share, in the same period a year earlier.

Adjusted earnings were 57 cents a share. Analysts had forecast adjusted earnings of 42 cents a share.

Abbott also reinstated full-year guidance, forecasting adjusted earnings of at least $3.25 a share, with a spokesman attributing the outlook to momentum the company is beginning to register. Abbott had canceled previous guidance in April, citing uncertainty about the course of the pandemic.

Write to Matt Grossman at matt.grossman@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.72% 105.19 Delayed Quote.21.10%
EURO / BRAZILIAN REAL (EUR/BRL) -0.12% 6.6077 Delayed Quote.46.76%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.47% 79.2956 Delayed Quote.27.37%
share with twitter share with LinkedIn share with facebook
All news about ABBOTT LABORATORIES
09/29WALL STREET STOCK EXCHANGE : U.S. Stocks Open Lower Ahead of First Trump-Biden D..
DJ
09/29ABBOTT LABORATORIES : Freestyle libre 3 system receives ce mark, features world'..
AQ
09/29U.S. Stock Futures Pause Ahead of First Trump-Biden Debate
DJ
09/29U.S. Stock Futures Pause Ahead of First Trump-Biden Debate
DJ
09/29U.S. Stock Futures Pause Ahead of First Trump-Biden Debate
DJ
09/29U.S. Stock Futures Pause Ahead of First Trump-Biden Debate
DJ
09/29U.S. Stock Futures Pause Ahead of First Trump-Biden Debate
DJ
09/28ABBOTT LABORATORIES : Glucose Monitor Gets European Approval
DJ
09/28ABBOTT : 's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smalle..
PR
09/23Positive about flying? Airlines look to COVID tests that give results in minu..
RE
More news
Financials (USD)
Sales 2020 33 067 M - -
Net income 2020 3 667 M - -
Net Debt 2020 12 312 M - -
P/E ratio 2020 50,8x
Yield 2020 1,38%
Capitalization 186 B 186 B -
EV / Sales 2020 6,00x
EV / Sales 2021 5,24x
Nbr of Employees 107 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 113,44 $
Last Close Price 105,19 $
Spread / Highest target 23,6%
Spread / Average Target 7,84%
Spread / Lowest Target -22,0%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES21.10%186 242
MEDTRONIC PLC-9.48%139 301
BECTON, DICKINSON AND COMPANY-17.11%65 220
HOYA CORPORATION14.35%41 770
BAXTER INTERNATIONAL INC.-5.42%40 266
DEXCOM, INC.83.86%38 315